Pre-clinical studies and various ongoing clinical trials evaluating the potential benefit of IL-6 blockers, for example, early α-IL-6 mAb and later α-IL-6R mAb, for the treatment of patients with CRS may provide clinical correlation with the results presented here. This evidence concerns the gene IL6 and congenital rubella syndrome.